SMC Accepts First Drug to Improve Survival in Uveal Melanoma
Scotland approves tebentafusp for metastatic uveal melanoma, a rare eye cancer with a median survival of around 12 months. Medscape News UK
Read the full article3d agoen
You might also wanna read
Tentacular Cyclosporiasis Outbreak Stymies Epidemiology Efforts
Medscape·4h ago
Tavapadon Improves Early PD Symptoms: Full Phase 3 Results
Medscape·4h ago
Medical Cannabis: What to Tell Your Patients
Medscape·4h ago
Grumblings Over CKM Guideline Not Warranted, Experts Say
Medscape·5h ago
GLP-1s May Reduce Overdose Risk, Even After Discontinuation
Medscape·5h ago
Population-Wide CRC Screening May Cut Health Inequities
Medscape·5h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.